Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its epilepsy programs at the following upcoming meetings in Orlando, Florida. Presentations at the American Epilepsy Society (AES) Annual Meeting, as well as related scientific and patient advocacy meetings, will cover new patient data, updates on clinical progress and new paradigms for developing epilepsy therapies.
Related news for (PRAX)
- Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event
- Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
- Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
- Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
- Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome